Company profile: BiVictriX Therapeutics
1.1 - Company Overview
Company description
- Provider of oncology and haematological malignancy drug discovery and development, biotherapeutics, immunotherapy, and antibody research, specializing in bispecific ADC therapeutics. Offers BVX001, a bispecific ADC targeting CD33/CD7 for Acute Myeloid Leukaemia (AML), and Bi-Cygni Therapeutics, targeting cancer-specific antigen pairs to improve selectivity and reduce toxicity.
Products and services
- Bi-Cygni® Therapeutics: Proprietary therapeutics selectively target cancer-specific antigen pairs, aiming to deliver higher doses of treatment with reduced toxicity across oncology indications
- BVX001: Custom-engineered bispecific Antibody Drug Conjugate targeting CD33/CD7 for Acute Myeloid Leukaemia, architected to improve cancer cell selectivity and reduce side effects
- Oncology and Haematological Malignancies Drug Discovery & Development: Integrated services advancing bispecific ADC therapeutics, biotherapeutics, immunotherapy, antibody research, and drug development across oncology and haematological malignancies
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to BiVictriX Therapeutics
OnKure Therapeutics
HQ: United States
Website
- Description: Provider of next-generation oncology precision medicines targeting validated cancer drivers, developed by a clinical-stage biopharma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OnKure Therapeutics company profile →
Foundation Medicine
HQ: United States
Website
- Description: Provider of molecular information and clinical diagnostic tests for personalized cancer care, including FoundationOne CDx tissue-based comprehensive genomic profiling, FoundationOne Liquid CDx blood-based ctDNA profiling, FoundationOne Heme for hematologic malignancies, FoundationOne RNA fusion detection in solid tumors, the FoundationCore cancer genomic database, and Molecular Tumor Boards.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Foundation Medicine company profile →
Novacyt
HQ: France
Website
- Description: Provider of in vitro and molecular diagnostic tests and cellular diagnostics, with a growing portfolio in cancer and infectious disease, offering diagnostics product development, commercialisation, and contract design and manufacturing via Primerdesign and Lab21 Products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Novacyt company profile →
Armune Bioscience
HQ: United States
Website
- Description: Provider of molecular diagnostic and prognostic tests for prostate, lung and breast cancers, enabling physicians and patients to make more personalized treatment decisions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Armune Bioscience company profile →
IDRx
HQ: United States
Website
- Description: Provider of oncology-based precision therapies for gastrointestinal stromal tumors (GIST). The clinical-stage biopharma designs precision combination medicines with engineered drug combinations to stop key tumor escape mechanisms and prolong response. Pipeline includes IDRX-42, a Phase 1 small-molecule tyrosine kinase inhibitor targeting genetic drivers and resistance mutations in GIST, and IDRX-73 targeting a key drug resistance mutation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IDRx company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for BiVictriX Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to BiVictriX Therapeutics
2.2 - Growth funds investing in similar companies to BiVictriX Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for BiVictriX Therapeutics
4.2 - Public trading comparable groups for BiVictriX Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →